DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Icrucumab
Icrucumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
The Future of Antibodies As Cancer Drugs
The Two Tontti Tudiul Lui Hi Ha Unit
Role of Vegfs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models
(INN) for Biological and Biotechnological Substances
Pdf Garcia-Carbonero R, Et Al
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
(12) Patent Application Publication (10) Pub. No.: US 2016/0184445 A1 Perroth Et Al
(INN) for Biological and Biotechnological Substances
Electrolyte Disorders Associated with the Use of Anticancer Drugs
Ramucirumab As a Second-Line Treatment for Locally Advanced Or Metastatic Urothelial Carcinoma: a Meta- Analysis of Randomized Clinical Trials †
Top View
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Riport Letöltése
( 12 ) United States Patent
Ramucirumab (Cyramza®) Approved By: UM Pharmacy Subcommittee
Colorectal Cancer: from Genetic Landscape to Targeted Therapy
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Patterns in Target-Directed Breast Cancer Research
Tumor Angiogenesis Revisited: Regulators and Clinical Implications
Pathogenetic Features and Current Management of Glioblastoma
PCORI Topic Brief: Comparative Effectiveness of Second-Line
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Oncompass Report NÉV Anonymous a Realtime Oncology Molecular Treatment Calculator Számításaival
WO 2015/038782 Al 19 March 2015 (19.03.2015) P O P C T
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
Novel Molecular Targets for the Therapy of Urothelial Cancer
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy
Ep 3088005 A1
Monoclonal Antibodies in Cancer Therapy
(19) United States Mar. 12, 2015
Bevacizumab Or Cetuximab Or Crizotinib Or Dasatinib Or
Oncology Drugs in the Pipeline
Ramucirumab in the Second-Line Treatment of Metastatic Colorectal Cancer: a Narrative Review of Literature from Clinical Trials
Earnings Presentation
Comprehensive Review of Targeted Therapy for Colorectal Cancer
New Therapeutic Approaches to Bladder Cancer Daniel P
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Report on the Deliberation Results May 16, 2016 Evaluation And
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT
Cyramza Utilization Management Medical Policy • Cyramza® (Ramucirumab Intravenous Infusion – Eli Lilly)